Literature DB >> 16284993

Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas.

Hai-Ning Zhen1, Xiang Zhang, Pei-Zhen Hu, Tong-Tao Yang, Zhou Fei, Jian-Ning Zhang, Luo-An Fu, Xiao-Sheng He, Fu-Cheng Ma, Xi-Ling Wang.   

Abstract

BACKGROUND: An unbalance of cell proliferation and cell apoptosis is an important mechanism in carcinogenesis, and angiogenesis also plays a crucial role in tumorigenesis. Recently, survivin has been identified as an important member of the inhibitor of apoptosis protein (IAP) family. Although it has been shown that survivin is highly expressed in gliomas, and is associated with tumorigenesis, progression, and poor prognosis of gliomas, as yet the relation of survivin expression with proliferation, apoptosis, and angiogenesis of gliomas it is still unclear.
METHODS: Eighty-three cases of brain glioma were chosen and protein expressions of survivin and proliferating cell nuclear antigen (PCNA) in glioma cells and Factor VIII-related antigen (FVIII-RAg) in vascular endothelial cells were investigated by immunohistochemistry. Apoptotic cells of brain glioma were screened by TdT-mediated dUTP nick end-labeling (TUNEL), and survivin immunoreactivity score (IRS), proliferative index (PI), apoptotic index (AI), overall daily growth (ODG), and microvessel density (MVD) in brain gliomas were measured.
RESULTS: The survivin IRS, PI, AI, ODG, and MVD of brain gliomas were 3.75 +/- 3.89, 28.39 +/- 19.49%, 1.00 +/- 0.80%, 12.19 +/- 10.21%, and 62.75 +/- 31.50, respectively, and all of them increased markedly with an increase in the pathologic grade of brain gliomas (P < 0.001 for all). PI, ODG, and MVD in the survivin-positive group were significantly higher than those in the survivin-negative group (P < 0.001 for all). PI, ODG, and MVD were positively correlated with survivin IRS (P < 0.001 for all). Although there was no significant difference between AI in the survivin-positive group or in the survivin-negative group (P = 0.108), AI was inversely correlated with survivin IRS (P = 0.005).
CONCLUSIONS: Survivin is overexpressed in brain gliomas, which may play an important role in malignant proliferation, antiapoptosis, and angiogenesis of brain gliomas. Copyright 2005 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16284993     DOI: 10.1002/cncr.21490

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

1.  The impact of survivin on prognosis and clinicopathology of glioma patients: a systematic meta-analysis.

Authors:  Shunzeng Lv; Congxin Dai; Yuting Liu; Ranran Shi; Zhenyu Tang; Mingzhi Han; Ruixiang Bian; Bowen Sun; Renzhi Wang
Journal:  Mol Neurobiol       Date:  2014-07-27       Impact factor: 5.590

Review 2.  Ependymomas: development of immunotherapeutic strategies.

Authors:  Ian F Pollack; Regina I Jakacki; Lisa H Butterfield; Hideho Okada
Journal:  Expert Rev Neurother       Date:  2013-10       Impact factor: 4.618

Review 3.  Mechanisms of resistance to photodynamic therapy.

Authors:  A Casas; G Di Venosa; T Hasan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

4.  Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment.

Authors:  Nobuyuki Kawai; Hai-Ning Zhen; Keisuke Miyake; Yuka Yamamaoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  J Neurooncol       Date:  2010-11       Impact factor: 4.130

5.  Functional analysis of KIF20A, a potential immunotherapeutic target for glioma.

Authors:  Katsuya Saito; Shigeki Ohta; Yutaka Kawakami; Kazunari Yoshida; Masahiro Toda
Journal:  J Neurooncol       Date:  2017-01-09       Impact factor: 4.130

6.  Survivin transcript variant 2 drives angiogenesis and malignant progression in proneural gliomas.

Authors:  Tiffany Doucette; Khatri Latha; Yuhui Yang; Gregory N Fuller; Arvind Rao; Ganesh Rao
Journal:  Neuro Oncol       Date:  2014-03-27       Impact factor: 12.300

7.  Evaluation of 3'-deoxy-3'-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas.

Authors:  Aya Shinomiya; Nobuyuki Kawai; Masaki Okada; Keisuke Miyake; Takehiro Nakamura; Yoshio Kushida; Reiji Haba; Nobuyuki Kudomi; Yuka Yamamoto; Masaaki Tokuda; Takashi Tamiya
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-15       Impact factor: 9.236

8.  Antitumor effect of mSurvivinThr34→Ala in murine colon carcinoma when administered intravenously.

Authors:  Hong-xia Li; Xin-yu Zhao; Lian Wang; Yong-sheng Wang; Bin Kan; Jian-rong Xu; Jiong Li; Yan-Jun Wen; Xing-chen Peng; Xiang Chen; Fei Yan; Bin Ye; Xiao-bo Du; Ju-mei Zhao; Tao Yi; Xian-cheng Chen; Xiao-xia Du; Yu-quan Wei; Xia Zhao
Journal:  Med Oncol       Date:  2009-12-01       Impact factor: 3.064

9.  Hyperglycemia attenuates angiogenic capability of survivin in endothelial cells.

Authors:  Qinhui Song; Xiaojin An; Dongmei Li; Neel R Sodha; Munir Boodhwani; Ye Tian; Frank W Sellke; Jian Li
Journal:  Microvasc Res       Date:  2009-08-27       Impact factor: 3.514

10.  Correlation of L-methyl-11C-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas.

Authors:  Shuichi Okubo; Hai-Ning Zhen; Nobuyuki Kawai; Yoshihiro Nishiyama; Reiji Haba; Takashi Tamiya
Journal:  J Neurooncol       Date:  2010-01-21       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.